Hideki Iijima
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hideki Iijima has a total of 348 co-authors. Here are the top co-authors by number of shared publications:
Masahiko Tsujii
Department of Gastroenterology, Higashiosaka City Medical Center, Higashiosaka, Osaka, Japan
72 shared publications- Tetsuo Takehara
Department of Gastroenterology and Hepatology, Kansai Rosai Hospital, Amagasaki, Japan
66 shared publications - Shinichiro Shinzaki
Department of Gastroenterology, Hyogo Medical University School of Medicine, Nishinomiya, Japan
64 shared publications - Tsutomu Nishida
Department of Gastroenterology, Toyonaka Municipal Hospital, Toyonaka, Japan
54 shared publications Satoshi Hiyama
38 shared publicationsYoshito Hayashi
Department of Gastroenterology and Hepatology, Osaka University Graduate School of Medicine, Osaka, Japan
38 shared publications
Latest Publications
- Open Access
- 8 July 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
Serum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis
Background and Aims: Effective, minimally invasive biomarkers are needed to predict treatment outcomes in ulcerative colitis (UC). This multicenter observational study investigated predictive serum and genetic biomarkers for vedolizumab (VDZ) therapy in UC, including serum leucine-rich α-2-glycoprotein (LRG), cytokines, and differentially expressed genes (DEGs) in intestinal tissue. Methods: Eligible patients (18-80 years; moderately to severely active UC) received intravenous VDZ (300 mg; Weeks 0, 2, 6, then every 8 weeks through Week 54). Serum biomarkers were compared between those who did/did not achieve clinical remission (CR; full Mayo score ≤2, all subscores ≤1) or mucosal healing (MH; Mayo endoscopic subscore ≤1) at Week 14. Week 0 inflammatory tissue data were stratified by Week 14 VDZ effect (CR and complete-MH [Mayo endoscopic subscore = 0]) for DEGs. Results: Overall, 21 patients were included. Mean serum LRG was significantly lower in the CR (n = 11) versus non-CR (n = 10) group at Week 0 (19.0 vs 29.0 µg/mL; P = .0267) and Week 6 (13.4 vs 19.6 µg/mL; P = .0340), and in the MH (n = 14) versus non-MH (n = 7) group at Week 6 (13.7 vs 21.6 µg/mL; P = .0326). Mean monocyte chemoattractant protein-1 (MCP-1) was significantly different between CR and non-CR groups at Week 0 (609.0 vs 403.4 pg/mL; P = .0018) and MH versus non-MH at Week 0 (587.2 vs 358.9 pg/mL; P < .001) and Week 6 (606.9 vs 451.6 pg/mL; P = .037). No significant differences in C-reactive protein and fecal calprotectin levels were observed. DEGs included LRG1, LRG-related cytokines, and MCP1. Conclusions: Serum LRG and MCP-1 may be candidate biomarkers of VDZ treatment response in UC.
- 8 July 2026
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 8 (3)
Open AccessSerum leucine-rich α-2-glycoprotein and monocyte chemoattractant protein-1 as novel biomarkers for predicting vedolizumab response in patients with ulcerative colitis
Background and Aims: Effective, minimally invasive biomarkers are needed to predict treatment outcomes in ulcerative colitis (UC). This multicenter observational study investigated predictive serum and genetic biomarkers for vedolizumab (VDZ) therapy in UC, including serum leucine-rich α-2-glycoprotein (LRG), cytokines, and differentially expressed genes (DEGs) in intestinal tissue. Methods: Eligible patients (18-80 years; moderately to severely active UC) received intravenous VDZ (300 mg; Weeks 0, 2, 6, then every 8 weeks through Week 54). Serum biomarkers were compared between those who did/did not achieve clinical remission (CR; full Mayo score ≤2, all subscores ≤1) or mucosal healing (MH; Mayo endoscopic subscore ≤1) at Week 14. Week 0 inflammatory tissue data were stratified by Week 14 VDZ effect (CR and complete-MH [Mayo endoscopic subscore = 0]) for DEGs. Results: Overall, 21 patients were included. Mean serum LRG was significantly lower in the CR (n = 11) versus non-CR (n = 10) group at Week 0 (19.0 vs 29.0 µg/mL; P = .0267) and Week 6 (13.4 vs 19.6 µg/mL; P = .0340), and in the MH (n = 14) versus non-MH (n = 7) group at Week 6 (13.7 vs 21.6 µg/mL; P = .0326). Mean monocyte chemoattractant protein-1 (MCP-1) was significantly different between CR and non-CR groups at Week 0 (609.0 vs 403.4 pg/mL; P = .0018) and MH versus non-MH at Week 0 (587.2 vs 358.9 pg/mL; P < .001) and Week 6 (606.9 vs 451.6 pg/mL; P = .037). No significant differences in C-reactive protein and fecal calprotectin levels were observed. DEGs included LRG1, LRG-related cytokines, and MCP1. Conclusions: Serum LRG and MCP-1 may be candidate biomarkers of VDZ treatment response in UC.
- Open Access
- 30 May 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3)
Optimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study
Background: There are currently no standardized guidelines for optimizing 5-aminosalicylic acid (5-ASA) maintenance treatment, particularly in patients with ulcerative colitis (UC) who have achieved clinical remission (CR). Therefore, this study examined the perspectives of patients and physicians regarding 5-ASA dose reduction and medication adherence to optimize maintenance treatment. Methods: This cross-sectional study was conducted from February 2023 to May 2023 at 19 institutions and included patients with UC and physicians. The participants’ perspectives were assessed using an anonymous questionnaire. Results: This study included 369 patients with UC (female, 43.1%; age, > 60 years, 29.3%; CR, 88.9%). Preference to reduce the 5-ASA dose and low medication adherence were observed in 46.1% and 16.0% of patients, respectively. Low medication adherence (odds ratio [OR]: 3.43, 95% confidence interval [CI]: 1.67–7.03) was associated with the preference to reduce the 5-ASA dose. Multivariate analysis for factors associated with low medication adherence revealed age < 60 years (OR: 10.25, 95% CI: 3.58–29.38), no intractable disease subsidy (OR: 2.63, 95% CI: 1.09–6.35), dosing frequency ≥ 2 times/day (OR: 9.04, 95% CI: 3.67–22.25), and preference to reduce the 5-ASA dose (OR: 2.57, 95% CI: 1.16–5.70) as significant. Among 153 physicians, 62.7% had > 10 years of experience, and 51.0% regularly verified adherence, with experience being a significant factor (OR: 2.01, 95% CI: 1.10–3.68). Conclusions: Factors influencing medication adherence with 5-ASA included patients’ desire for dose reduction and physicians’ lack of experience. Improving communication with patients and enhancing education for physicians could help optimize treatment with 5-ASA.
- 30 May 2025
- Published by Oxford University Press (OUP) in Crohn's & Colitis 360
- Vol. 7 (3)
Open AccessOptimizing 5-Aminosalicylic Acid Maintenance Treatment in Ulcerative Colitis from the Patient and Physician Perspective: A Cross-sectional Multicenter Study
Background: There are currently no standardized guidelines for optimizing 5-aminosalicylic acid (5-ASA) maintenance treatment, particularly in patients with ulcerative colitis (UC) who have achieved clinical remission (CR). Therefore, this study examined the perspectives of patients and physicians regarding 5-ASA dose reduction and medication adherence to optimize maintenance treatment. Methods: This cross-sectional study was conducted from February 2023 to May 2023 at 19 institutions and included patients with UC and physicians. The participants’ perspectives were assessed using an anonymous questionnaire. Results: This study included 369 patients with UC (female, 43.1%; age, > 60 years, 29.3%; CR, 88.9%). Preference to reduce the 5-ASA dose and low medication adherence were observed in 46.1% and 16.0% of patients, respectively. Low medication adherence (odds ratio [OR]: 3.43, 95% confidence interval [CI]: 1.67–7.03) was associated with the preference to reduce the 5-ASA dose. Multivariate analysis for factors associated with low medication adherence revealed age < 60 years (OR: 10.25, 95% CI: 3.58–29.38), no intractable disease subsidy (OR: 2.63, 95% CI: 1.09–6.35), dosing frequency ≥ 2 times/day (OR: 9.04, 95% CI: 3.67–22.25), and preference to reduce the 5-ASA dose (OR: 2.57, 95% CI: 1.16–5.70) as significant. Among 153 physicians, 62.7% had > 10 years of experience, and 51.0% regularly verified adherence, with experience being a significant factor (OR: 2.01, 95% CI: 1.10–3.68). Conclusions: Factors influencing medication adherence with 5-ASA included patients’ desire for dose reduction and physicians’ lack of experience. Improving communication with patients and enhancing education for physicians could help optimize treatment with 5-ASA.
- Open Access
- 1 January 2025
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 10 (1) , 254-264
Safety and Effectiveness of Oral Budesonide after Endoscopic Balloon Dilation in Patients with Crohn’s Disease: A Multicenter Prospective Intervention Study
Introduction: Budesonide, with its high topical steroidal activity, effectively prevents strictures following esophageal endoscopic treatment. However, its effectiveness in preventing restenosis after endoscopic balloon dilation (EBD) in patients with Crohn’s disease (CD) remains unclear. We aimed to evaluate the safety and effectiveness of oral budesonide after EBD in patients with CD. Methods: We conducted a multicenter prospective study of patients with CD who underwent EBD at the University of Osaka and its affiliated hospitals between March 2018 and March 2023 (UMIN000031839, jRCT1051190043). Oral budesonide was administered for 4 weeks after EBD, and patients were followed up for 52 weeks. Safety and effectiveness within 12 and 52 weeks of the procedure were evaluated, with endoscopic evaluation of restenosis at week 52. The stenosis diameter and length were estimated endoscopically and radiographically, respectively. In the historical control study, consecutive patients with CD who underwent EBD between February 2016 and July 2018 were included. The incidence rates of obstructive symptoms and hospitalization at 52 weeks after EBD were retrospectively investigated from the medical records. Results: Overall, 15 patients were analyzed (male, 14 [93.3%]; median age, 44 years [37–49]; disease type, L1, 8 [53.3%]/L3, 7 [46.7%]; stenosis location, jejunum, 1 [6.7%]/ileum, 8 [53.3%]/ileocolonic, 6 [40.0%]; median stenosis diameter, 5 mm [5–6]). No serious complications were observed within 12 or 52 weeks. Twelve (80%) patients showed no symptoms of stenosis within 52 weeks. Of the 14 patients who underwent an endoscopy at week 52, re-EBD was not required in 3 patients (21.4%). The stenosis diameter at week 52 improved significantly compared to the pre-dilation measurements (p = 0.004). Furthermore, the 15 patients treated with budesonide had a significantly lower incidence rates of obstructive symptoms and hospitalization compared to the 19 historical control patients (p = 0.020 and 0.035, respectively). Conclusion: Budesonide administration after EBD can be safely performed in patients with CD and may be effective in preventing restenosis and avoiding hospitalization and intestinal surgery.
- 1 January 2025
- Published by S. Karger AG in Inflammatory Intestinal Diseases
- Vol. 10 (1) , 254-264
Open AccessSafety and Effectiveness of Oral Budesonide after Endoscopic Balloon Dilation in Patients with Crohn’s Disease: A Multicenter Prospective Intervention Study
Introduction: Budesonide, with its high topical steroidal activity, effectively prevents strictures following esophageal endoscopic treatment. However, its effectiveness in preventing restenosis after endoscopic balloon dilation (EBD) in patients with Crohn’s disease (CD) remains unclear. We aimed to evaluate the safety and effectiveness of oral budesonide after EBD in patients with CD. Methods: We conducted a multicenter prospective study of patients with CD who underwent EBD at the University of Osaka and its affiliated hospitals between March 2018 and March 2023 (UMIN000031839, jRCT1051190043). Oral budesonide was administered for 4 weeks after EBD, and patients were followed up for 52 weeks. Safety and effectiveness within 12 and 52 weeks of the procedure were evaluated, with endoscopic evaluation of restenosis at week 52. The stenosis diameter and length were estimated endoscopically and radiographically, respectively. In the historical control study, consecutive patients with CD who underwent EBD between February 2016 and July 2018 were included. The incidence rates of obstructive symptoms and hospitalization at 52 weeks after EBD were retrospectively investigated from the medical records. Results: Overall, 15 patients were analyzed (male, 14 [93.3%]; median age, 44 years [37–49]; disease type, L1, 8 [53.3%]/L3, 7 [46.7%]; stenosis location, jejunum, 1 [6.7%]/ileum, 8 [53.3%]/ileocolonic, 6 [40.0%]; median stenosis diameter, 5 mm [5–6]). No serious complications were observed within 12 or 52 weeks. Twelve (80%) patients showed no symptoms of stenosis within 52 weeks. Of the 14 patients who underwent an endoscopy at week 52, re-EBD was not required in 3 patients (21.4%). The stenosis diameter at week 52 improved significantly compared to the pre-dilation measurements (p = 0.004). Furthermore, the 15 patients treated with budesonide had a significantly lower incidence rates of obstructive symptoms and hospitalization compared to the 19 historical control patients (p = 0.020 and 0.035, respectively). Conclusion: Budesonide administration after EBD can be safely performed in patients with CD and may be effective in preventing restenosis and avoiding hospitalization and intestinal surgery.
- 16 June 2022
- Published by S. Karger AG in Digestion
- Vol. 103 (5) , 347-356
Clinical and Histopathological Features of the Differentiated Type of Early Gastric Cancer with an Unclear Lateral Demarcation
Introduction: Magnifying endoscopy with narrow-band imaging (M-NBI) is useful for determining lateral demarcation of early gastric cancers; however, this is sometimes difficult. Features related to an unclear lateral demarcation remain unknown. We evaluated the clinical and histopathological features of early gastric cancers with unclear lateral demarcation on M-NBI. Methods: This single-center, retrospective, cohort study analyzed early gastric cancer treated by endoscopic submucosal dissection between January 2013 and August 2015. We evaluated the clinicopathological and immunohistochemical features using anti-p53, anti-Ki-67, anti-MUC5AC, anti-MUC6, anti-MUC2, and anti-CD10 antibody staining. We compared the lateral demarcation between the demarcation clear (DC) and the demarcation unclear (DU) lesions by using M-NBI. Results: A total of 224 differentiated adenocarcinomas (DU group: 18 lesions; DC group: 206 lesions) were analyzed. A history of successful Helicobacter pylori eradication was significantly more frequent in the DU group (p = 0.001). We examined the tissues of 72 lesions (DU group: 18 lesions, DC group: 54 lesions [randomly selected]) immunohistochemically. The nonneoplastic superficial epithelium was observed more frequently in the DU group as compared to in the DC group (p = 0.006). Additionally, compared to the DC group, the DU group showed a significantly higher expression of the gastric phenotype markers (p = 0.023) and had lower p53 scores (p < 0.001) and Ki-67 labeling indexes (p = 0.029). Multivariate analysis revealed the nonneoplastic superficial epithelium and a low p53 score as the significant independent variables associated with an unclear lateral demarcation on M-NBI. Conclusions: The nonneoplastic superficial epithelium and a low p53 score were associated with difficulties in determining the lateral demarcation in early gastric cancers on M-NBI.
- 16 June 2022
- Published by S. Karger AG in Digestion
- Vol. 103 (5) , 347-356
Clinical and Histopathological Features of the Differentiated Type of Early Gastric Cancer with an Unclear Lateral Demarcation
Introduction: Magnifying endoscopy with narrow-band imaging (M-NBI) is useful for determining lateral demarcation of early gastric cancers; however, this is sometimes difficult. Features related to an unclear lateral demarcation remain unknown. We evaluated the clinical and histopathological features of early gastric cancers with unclear lateral demarcation on M-NBI. Methods: This single-center, retrospective, cohort study analyzed early gastric cancer treated by endoscopic submucosal dissection between January 2013 and August 2015. We evaluated the clinicopathological and immunohistochemical features using anti-p53, anti-Ki-67, anti-MUC5AC, anti-MUC6, anti-MUC2, and anti-CD10 antibody staining. We compared the lateral demarcation between the demarcation clear (DC) and the demarcation unclear (DU) lesions by using M-NBI. Results: A total of 224 differentiated adenocarcinomas (DU group: 18 lesions; DC group: 206 lesions) were analyzed. A history of successful Helicobacter pylori eradication was significantly more frequent in the DU group (p = 0.001). We examined the tissues of 72 lesions (DU group: 18 lesions, DC group: 54 lesions [randomly selected]) immunohistochemically. The nonneoplastic superficial epithelium was observed more frequently in the DU group as compared to in the DC group (p = 0.006). Additionally, compared to the DC group, the DU group showed a significantly higher expression of the gastric phenotype markers (p = 0.023) and had lower p53 scores (p < 0.001) and Ki-67 labeling indexes (p = 0.029). Multivariate analysis revealed the nonneoplastic superficial epithelium and a low p53 score as the significant independent variables associated with an unclear lateral demarcation on M-NBI. Conclusions: The nonneoplastic superficial epithelium and a low p53 score were associated with difficulties in determining the lateral demarcation in early gastric cancers on M-NBI.
- Open Access
- 24 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (7)
Lysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.
- 24 May 2022
- Published by Rockefeller University Press in Journal of Experimental Medicine
- Vol. 219 (7)
Open AccessLysophosphatidylserines derived from microbiota in Crohn’s disease elicit pathological Th1 response
Microbiota alteration and IFN-γ–producing CD4+ T cell overactivation are implicated in Crohn’s disease (CD) pathogenesis. However, it remains unclear how dysbiosis enhances Th1 responses, leading to intestinal inflammation. Here, we identified key metabolites derived from dysbiotic microbiota that induce enhanced Th1 responses and exaggerate colitis in mouse models. Patients with CD showed elevated lysophosphatidylserine (LysoPS) concentration in their feces, accompanied by a higher relative abundance of microbiota possessing a gene encoding the phospholipid-hydrolyzing enzyme phospholipase A. LysoPS induced metabolic reprogramming, thereby eliciting aberrant effector responses in both human and mouse IFN-γ–producing CD4+ T cells. Administration of LysoPS into two mouse colitis models promoted large intestinal inflammation. LysoPS-induced aggravation of colitis was impaired in mice lacking P2ry10 and P2ry10b, and their CD4+ T cells were hyporesponsive to LysoPS. Thus, our findings elaborate on the mechanism by which metabolites elevated in patients with CD harboring dysbiotic microbiota promote Th1-mediated intestinal pathology.
- Open Access
- 28 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (8) , 1561-1570
Exacerbation of non‐steroidal anti‐inflammatory drug‐induced enteropathy in C‐C chemokine receptor type 7‐deficient mice
Background and Aim: Non‐steroidal anti‐inflammatory drugs (NSAIDs) induce intestinal enteropathy and the pathophysiology is related to immune‐mediated mechanisms. We aimed to investigate the role of C‐C chemokine receptor type 7 (CCR7) which regulates immune cell migration in NSAID‐induced enteropathy.Methods: Injury of the small intestine was evaluated 24 h after the subcutaneous injection of indomethacin in CCR7‐deficient (Ccr7−/−) and wild‐type (WT) mice. The cellular profile and cytokine production in intestinal cells were analyzed. Indomethacin‐induced enteropathy was evaluated in mice adoptively transferred with CD103+ dendritic cells (DCs) from Ccr7−/− or WT mice.Results: Indomethacin induced more severe intestinal injury in Ccr7−/− mice than in WT mice. The major inflammatory cytokines were not increased and the proportion of regulatory T cells following indomethacin injection was not decreased in Ccr7−/− mice compared with WT mice. The expression of interleukin (IL)‐22 binding protein (IL‐22BP), which inhibits IL‐22 activity, was significantly higher in CD103+ DCs from Ccr7−/− mice than those from WT mice. Mice adoptively transferred with CD103+ DCs isolated from Ccr7−/− mice exhibited more severe intestinal injury following indomethacin injection compared with those adoptively transferred with CD103+ DCs of WT mice. Ccr7−/− mice injected with indomethacin showed a significant reduction in regenerating islet‐derived 1 (Reg1) mRNA expression, which is regulated by IL‐22, in intestinal epithelial cells.Conclusions: C‐C chemokine receptor type 7 deficiency exacerbated NSAID‐induced enteropathy in association with an altered phenotype of CD103+ DCs that produces IL‐22BP. CCR7 contributes to protect the small intestine from NSAID‐induced mucosal injury.
- 28 April 2022
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 37 (8) , 1561-1570
Open AccessExacerbation of non‐steroidal anti‐inflammatory drug‐induced enteropathy in C‐C chemokine receptor type 7‐deficient mice
Background and Aim: Non‐steroidal anti‐inflammatory drugs (NSAIDs) induce intestinal enteropathy and the pathophysiology is related to immune‐mediated mechanisms. We aimed to investigate the role of C‐C chemokine receptor type 7 (CCR7) which regulates immune cell migration in NSAID‐induced enteropathy.Methods: Injury of the small intestine was evaluated 24 h after the subcutaneous injection of indomethacin in CCR7‐deficient (Ccr7−/−) and wild‐type (WT) mice. The cellular profile and cytokine production in intestinal cells were analyzed. Indomethacin‐induced enteropathy was evaluated in mice adoptively transferred with CD103+ dendritic cells (DCs) from Ccr7−/− or WT mice.Results: Indomethacin induced more severe intestinal injury in Ccr7−/− mice than in WT mice. The major inflammatory cytokines were not increased and the proportion of regulatory T cells following indomethacin injection was not decreased in Ccr7−/− mice compared with WT mice. The expression of interleukin (IL)‐22 binding protein (IL‐22BP), which inhibits IL‐22 activity, was significantly higher in CD103+ DCs from Ccr7−/− mice than those from WT mice. Mice adoptively transferred with CD103+ DCs isolated from Ccr7−/− mice exhibited more severe intestinal injury following indomethacin injection compared with those adoptively transferred with CD103+ DCs of WT mice. Ccr7−/− mice injected with indomethacin showed a significant reduction in regenerating islet‐derived 1 (Reg1) mRNA expression, which is regulated by IL‐22, in intestinal epithelial cells.Conclusions: C‐C chemokine receptor type 7 deficiency exacerbated NSAID‐induced enteropathy in association with an altered phenotype of CD103+ DCs that produces IL‐22BP. CCR7 contributes to protect the small intestine from NSAID‐induced mucosal injury.
- Open Access
- 31 August 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-10
Vascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA. This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins. A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.
- 31 August 2021
- Published by Springer Nature in BMC Cancer
- Vol. 21 (1) , 1-10
Open AccessVascular endothelial growth factor-A is an Immunohistochemical biomarker for the efficacy of bevacizumab-containing chemotherapy for duodenal and jejunal adenocarcinoma
The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA. This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor-A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins. A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30–0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.
- Open Access
- 16 July 2021
- Published by S. Karger AG in Digestion
- Vol. 102 (6) , 929-937
Leucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study
Introduction: The aim of this study was to examine whether biomarkers are predictive of the adalimumab (ADA) trough level and antidrug antibody development in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods: Using data obtained in a prospective, multicenter, observational study (PLANET), we assessed serial changes in a novel biomarker – leucine-rich alpha-2 glycoprotein (LRG) – during ADA treatment for patients with active CD and UC. We measured serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCAL) at weeks 0, 12, 24, and 52. The ADA trough level and anti-ADA antibody (AAA) were also measured at weeks 12 and 52. Correlations between the ADA trough level, AAA, and biomarkers were examined. Results: In all, 34 patients with CD and 47 patients with UC were enrolled. The ADA trough level at week 12 or at the time of ADA withdrawal was 8.5 ± 3.9 in the AAA-negative group (n = 70) and 2.9 ± 2.7 μg/mL in the AAA-positive group (n = 8) (p < 0.0001). The ADA trough level at week 12 or at the time of ADA withdrawal was associated with pretreatment LRG (p = 0.0437 and r = −0.23). Conclusion: LRG, rather than CRP or fCAL, may be a marker for predicting the trough level of ADA for patients with CD and UC treated with ADA.
- 16 July 2021
- Published by S. Karger AG in Digestion
- Vol. 102 (6) , 929-937
Open AccessLeucine-Rich Alpha-2 Glycoprotein May Be Predictive of the Adalimumab Trough Level and Antidrug Antibody Development for Patients with Inflammatory Bowel Disease: A Sub-Analysis of the PLANET Study
Introduction: The aim of this study was to examine whether biomarkers are predictive of the adalimumab (ADA) trough level and antidrug antibody development in patients with Crohn’s disease (CD) and ulcerative colitis (UC). Methods: Using data obtained in a prospective, multicenter, observational study (PLANET), we assessed serial changes in a novel biomarker – leucine-rich alpha-2 glycoprotein (LRG) – during ADA treatment for patients with active CD and UC. We measured serum LRG, C-reactive protein (CRP), and fecal calprotectin (fCAL) at weeks 0, 12, 24, and 52. The ADA trough level and anti-ADA antibody (AAA) were also measured at weeks 12 and 52. Correlations between the ADA trough level, AAA, and biomarkers were examined. Results: In all, 34 patients with CD and 47 patients with UC were enrolled. The ADA trough level at week 12 or at the time of ADA withdrawal was 8.5 ± 3.9 in the AAA-negative group (n = 70) and 2.9 ± 2.7 μg/mL in the AAA-positive group (n = 8) (p < 0.0001). The ADA trough level at week 12 or at the time of ADA withdrawal was associated with pretreatment LRG (p = 0.0437 and r = −0.23). Conclusion: LRG, rather than CRP or fCAL, may be a marker for predicting the trough level of ADA for patients with CD and UC treated with ADA.
- Open Access
- 21 April 2021
- Published by Springer Nature in Research Square
Vascular Endothelial Growth Factor-A is an Immunohistochemical Biomarker for the Efficacy of Bevacizumab-containing Chemotherapy for Duodenal and Jejunal Adenocarcinoma
Background: The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA.Methods: This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins.Results: A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30-0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. Conclusion: Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.
- 21 April 2021
- Published by Springer Nature in Research Square
Open AccessVascular Endothelial Growth Factor-A is an Immunohistochemical Biomarker for the Efficacy of Bevacizumab-containing Chemotherapy for Duodenal and Jejunal Adenocarcinoma
Background: The efficacy and safety of bevacizumab-containing chemotherapy for patients with metastatic duodenal and jejunal adenocarcinoma (mDJA) are unclear. The present study aimed to evaluate the efficacy of bevacizumab and to explore immunohistochemical markers that can predict the efficacy of bevacizumab for patients with mDJA.Methods: This multicentre study included patients with histologically confirmed small bowel adenocarcinoma who received palliative chemotherapy from 2008 to 2017 at 15 hospitals. Immunostaining was performed for vascular endothelial growth factor A (VEGF-A), TP53, Ki67, β-catenin, CD10, MUC2, MUC5AC, MUC6, and mismatch repair proteins.Results: A total of 74 patients were enrolled, including 65 patients with mDJA and 9 with metastatic ileal adenocarcinoma. Patients with mDJA who received platinum-based chemotherapy with bevacizumab as first-line treatment tended to have a longer progression-free survival and overall survival than those treated without bevacizumab (P = 0.075 and 0.077, respectively). Multivariate analysis extracted high VEGF-A expression as a factor prolonging progression-free survival (hazard ratio: 0.52, 95% confidence interval: 0.30-0.91). In mDJA patients with high VEGF-A expression, those who received platinum-based chemotherapy with bevacizumab as a first-line treatment had significantly longer progression-free survival and tended to have longer overall survival than those treated without bevacizumab (P = 0.025 and P = 0.056, respectively), whereas no differences were observed in mDJA patients with low VEGF-A expression. Conclusion: Immunohistochemical expression of VEGF-A is a potentially useful biomarker for predicting the efficacy of bevacizumab-containing chemotherapy for patients with mDJA.
- 15 January 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (7) , 1744-1753
Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta‐analysis
Background and Aim Ustekinumab (UST), a fully‐humanized monoclonal antibody against the p40 subunit of interleukin‐12/23, is effective for the treatment of Crohn's disease (CD). The benefit of concomitant use of an immunomodulator (IM) with UST, however, is unclear. This study aimed to provide a systematic review and meta‐analysis comparing the efficacy and safety of concomitant use of an IM with UST as an induction therapy for CD patients. Methods A systematic literature search was performed using Pubmed/MEDLINE, the Cochrane Library, and the Japana Centra Reuvo Medicina from inception to 31 October 2019. The main outcome measure was achievement of clinical efficacy (remission, response, and clinical benefit) at 6‐12 weeks. The quality of the included studies was assessed using the risk of bias in non‐randomized studies of interventions (ROBINS‐I) tools. The fixed‐effects model was used to calculate the pooled odds ratios (OR). Results From 189 yielded articles, 6 including a total of 1507 patients were considered in this meta‐analysis. Concomitant use of an IM with UST was significantly effective than UST monotherapy as an induction therapy (pooled OR in the fixed‐effects model: 1.35, 95%CI [1.06‐1.71], p=0.015). The heterogeneity among studies was low (I2 = 2.6%). No statistical comparisons of the occurrence of adverse events between UST monotherapy and concomitant use of an IM with UST were performed. Conclusion The efficacy of concomitant use of an IM with UST as an induction therapy for CD was significantly superior to that of monotherapy with UST.
- 15 January 2021
- Published by Wiley in Journal of Gastroenterology and Hepatology
- Vol. 36 (7) , 1744-1753
Concomitant use of an immunomodulator with ustekinumab as an induction therapy for Crohn's disease: A systematic review and meta‐analysis
Background and Aim Ustekinumab (UST), a fully‐humanized monoclonal antibody against the p40 subunit of interleukin‐12/23, is effective for the treatment of Crohn's disease (CD). The benefit of concomitant use of an immunomodulator (IM) with UST, however, is unclear. This study aimed to provide a systematic review and meta‐analysis comparing the efficacy and safety of concomitant use of an IM with UST as an induction therapy for CD patients. Methods A systematic literature search was performed using Pubmed/MEDLINE, the Cochrane Library, and the Japana Centra Reuvo Medicina from inception to 31 October 2019. The main outcome measure was achievement of clinical efficacy (remission, response, and clinical benefit) at 6‐12 weeks. The quality of the included studies was assessed using the risk of bias in non‐randomized studies of interventions (ROBINS‐I) tools. The fixed‐effects model was used to calculate the pooled odds ratios (OR). Results From 189 yielded articles, 6 including a total of 1507 patients were considered in this meta‐analysis. Concomitant use of an IM with UST was significantly effective than UST monotherapy as an induction therapy (pooled OR in the fixed‐effects model: 1.35, 95%CI [1.06‐1.71], p=0.015). The heterogeneity among studies was low (I2 = 2.6%). No statistical comparisons of the occurrence of adverse events between UST monotherapy and concomitant use of an IM with UST were performed. Conclusion The efficacy of concomitant use of an IM with UST as an induction therapy for CD was significantly superior to that of monotherapy with UST.